These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 24429202

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 4. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.
    Cochrane Database Syst Rev; 2016 Mar 10; 3():CD010429. PubMed ID: 26964506
    [Abstract] [Full Text] [Related]

  • 5. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium.
    Eur Urol; 2013 May 10; 63(5):927-35. PubMed ID: 23040208
    [Abstract] [Full Text] [Related]

  • 6. Bone health in cystic fibrosis: use of oral bisphosphonates.
    Le Henaff C, Velard F, Jacquot J.
    Lancet Respir Med; 2013 Jul 10; 1(5):349-50. PubMed ID: 24429188
    [No Abstract] [Full Text] [Related]

  • 7. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 8. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 9. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
    Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M.
    Osteoporos Int; 2006 Jun 15; 17(6):942-9. PubMed ID: 16550299
    [Abstract] [Full Text] [Related]

  • 10. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
    N Engl J Med; 2014 Jan 30; 370(5):412-20. PubMed ID: 24382002
    [Abstract] [Full Text] [Related]

  • 11. Randomized controlled trial of alendronate in airways disease and low bone mineral density.
    Smith BJ, Laslett LL, Pile KD, Phillips PJ, Phillipov G, Evans SM, Esterman AJ, Berry JG.
    Chron Respir Dis; 2004 Jan 30; 1(3):131-7. PubMed ID: 16281654
    [Abstract] [Full Text] [Related]

  • 12. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D, ANRS 120 Fosivir Study Group.
    AIDS Res Hum Retroviruses; 2012 Sep 30; 28(9):972-80. PubMed ID: 22353022
    [Abstract] [Full Text] [Related]

  • 13. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS, Chang AB.
    Cochrane Database Syst Rev; 2012 Apr 18; (4):CD002010. PubMed ID: 22513903
    [Abstract] [Full Text] [Related]

  • 15. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3.
    Gilfraguas L, Guadalix S, Martinez G, Jodar E, Vara J, Gomez-Sanchez MA, Delgado J, De La Cruz J, Lora D, Hawkins F.
    Prog Transplant; 2012 Sep 18; 22(3):237-43. PubMed ID: 22951500
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of alendronate in adults with cystic fibrosis with low bone density.
    Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, Neuringer IP, Chalermskulrat W, Ontjes DA.
    Am J Respir Crit Care Med; 2004 Jan 01; 169(1):77-82. PubMed ID: 14563654
    [Abstract] [Full Text] [Related]

  • 17. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).
    Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD.
    Chest; 2008 Oct 01; 134(4):794-800. PubMed ID: 18641106
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS, Chang AB.
    Cochrane Database Syst Rev; 2014 Mar 14; 2014(3):CD002010. PubMed ID: 24627308
    [Abstract] [Full Text] [Related]

  • 19. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM.
    N Engl J Med; 2003 Sep 25; 349(13):1216-26. PubMed ID: 14500805
    [Abstract] [Full Text] [Related]

  • 20. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.